Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 19/20 | 0.75 |
| ▸ | LCK | P06239 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.63 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422090 | 0.86 | EGFR (1.00) | EGFRERBB2LCKKDRAAK1 | |
| SCHEMBL4415698 | 0.86 | AAK1 (0.60) | EGFRERBB2LCKKDRAAK1 | |
| SCHEMBL4550635 | 0.85 | EGFR (0.79) | EGFRERBB2LCKKDRAAK1 | |
| SCHEMBL4423776 | 0.84 | EGFR (0.83) | EGFRERBB2LCKKDRAAK1 | |
| SCHEMBL6100376 | 0.83 | EGFR (1.00) | EGFRERBB2LCKKDR | |
| SCHEMBL6097768 | 0.83 | EGFR (0.78) | EGFRERBB2LCKKDRAAK1 | |
| SCHEMBL4563501 | 0.83 | EGFR (0.80) | EGFRERBB2LCKKDRAAK1 | |
| SCHEMBL4566398 | 0.83 | EGFR (1.00) | EGFRERBB2LCKKDRAAK1 | |
| SCHEMBL4419944 | 0.82 | EGFR (1.00) | EGFRERBB2LCKKDR | |
| SCHEMBL1220849 | 0.82 | EGFR (1.00) | EGFRERBB2LCKKDRAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699798-A4 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1699798-A2 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7064203-B2 | Di-substituted pyrrolotriazine compounds | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| WO-2005065266-A2 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | ERBB2, ERBB4, EGFR | EGFR 3/4885ERBB2 1/4885LCK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.